Against bronchiolitis, the effectiveness of Beyfortus in preventing serious infections confirmed
By The New Obs with AFP
Published on , updated on
Beyfortus, a treatment designed to immunize infants against the main virus that causes bronchiolitis, was developed by Sanofi in partnership with the British company AstraZeneca. FRED TANNEAU/AFP
Beyfortus, a treatment designed to immunize babies against the main virus that causes bronchiolitis, is highly effective in preventing serious respiratory syncytial virus (RSV) infections in infants, confirms a large analysis published this Friday, May 2.
Also read
Interview Infant mortality: a French scandal
National studies had already concluded that this treatment had limited hospitalizations of babies, but the one revealed in "The Lancet Child & Adolescent Health" provides the most solid overview to date of the state of knowledge.
Although it is generally not serious, bronchiolitis, which causes breathing difficulties, particularly in babies during the first 6 months of their life, can sometimes lead to trips to the emergency room and hospitalization.
Beyfortus is part of a series of innovative treatments aimed at preventing or limiting infection by the main virus that causes this disease. Nirsevimab, the name of the molecule, is not a vaccine, even though it is injectable, but a preventative treatment that prevents the virus from infecting the body.
An 83% reduction in the risk of hospitalizationFollowing successful clinical trials, this monoclonal antibody – developed by Sanofi in partnership with the British company AstraZeneca – was approved by several regulatory agencies in 2023 and subsequently made available in certain high-income countries.
Also read
Decryption Chickenpox, bronchiolitis… Will our children be sicker after the pandemic?
